SEARCH

SEARCH BY CITATION

Keywords:

  • ARID1A;
  • cancer;
  • chromatin remodeling

Abstract

  1. Top of page
  2. Abstract
  3. Acknowledgements
  4. References
  5. Supporting Information

Mutations in the chromatin remodeling gene ARID1A have recently been identified in the majority of ovarian clear cell carcinomas (OCCCs). To determine the prevalence of mutations in other tumor types, we evaluated 759 malignant neoplasms including those of the pancreas, breast, colon, stomach, lung, prostate, brain, and blood (leukemias). We identified truncating mutations in 6% of the neoplasms studied; nontruncating somatic mutations were identified in an additional 0.4% of neoplasms. Mutations were most commonly found in gastrointestinal samples with 12 of 119 (10%) colorectal and 10 of 100 (10%) gastric neoplasms, respectively, harboring changes. More than half of the mutated colorectal and gastric cancers displayed microsatellite instability (MSI) and the mutations in these tumors were out-of-frame insertions or deletions at mononucleotide repeats. Mutations were also identified in 2–8% of tumors of the pancreas, breast, brain (medulloblastomas), prostate, and lung, and none of these tumors displayed MSI. These findings suggest that the aberrant chromatin remodeling consequent to ARID1A inactivation contributes to a variety of different types of neoplasms. Hum Mutat 33:100–103, 2012. © 2011 Wiley Periodicals, Inc.

Advances in sequencing technologies and bioinformatics, coupled with the identification of the sequence of the human genome, have enabled more than a dozen tumor types to be evaluated for mutations over their entire exomes [Meyerson et al., 2010; Stratton, 2011]. These studies have demonstrated that the landscape of each particular tumor type is defined by a small number of genes mutated at a high frequency, called “gene mountains” and a larger number of gene “hills” that are present in a smaller proportion of cases [Wood et al., 2007].

Members of our group recently used next generation sequencing to evaluate the exomes of ovarian clear cell carcinomas (OCCCs) and identified truncating mutations in ARID1A (MIM# 603024) in 57% of these tumors [Jones et al., 2010]. Independently, Wiegand et al. [2010] discovered a high prevalence of ARID1A mutations in both OCCC (45%) and endometriod carcinoma of the ovary (30%). Combining both studies, two mutations were identified in the same tumor in 30% of the mutated cases, which, taken together with the inactivating nature of the mutations and their remarkable frequency, provided unequivocal evidence that ARID1A is a tumor suppressor gene in these two tumor types. In addition, loss of ARID1A expression was observed in approximately 20% of uterine carcinomas [Wiegand et al., 2011]. In previous studies, chromosomal translocations involving ARID1A were identified in a breast and a lung cancer, though the interpretation of these alterations was challenging [Huang et al., 2007].

The protein encoded by ARID1A is a key component of the highly conserved SWI–SNF (switch/sucrose non-fermentable) chromatin remodeling complex that uses adenosine triphosphate (ATP)-dependent helicase activities to allow access of transcriptional activators and repressors to DNA [Wang et al., 2004; Wilson and Roberts, 2011]. The protein therefore appears to be involved in regulating processes including DNA repair, differentiation, and development [Weissman et al., 2009]. Functional studies by Nagl et al. [2007] have demonstrated that the SWI–SNF complex suppresses proliferation. The ARID1A-encoded protein, BAF250a, is one of two mutually exclusive ARID1 subunits. BAF250a has a DNA-binding domain that specifically binds to AT-rich DNA sequences and is thought to confer specificity to the complex [Wu et al., 2009].

Passenger mutations are best defined as those that do not confer a selective growth advantage to the cells in which they occur, while driver mutations are those which do confer a growth advantage. It is often difficult to distinguish driver mutations from passenger mutations when the mutations occur at low frequency. One of the best examples of this challenge is provided by IDH1 mutations. A single mutation of IDH1, R132H, was discovered in a whole exomic screen of 11 colorectal cancers (CRCs) [Sjöblom et al., 2006]. This mutation was not identified in more than 200 additional CRC samples and was presumed to be a passenger mutation. However, frequent IDH1 mutations at the identical residue were found when brain tumors, such as lower grade astrocytomas and oligodendrogliomas were evaluated [Parsons et al., 2008; Yan et al., 2009]. Thus, the IDH1 mutation in that original CRC in retrospect was undoubtedly a driver.

This example illustrates that once a genetic alteration is identified as a driver in one tumor type, infrequent mutations of the same type in the same gene in other tumors can be more reliably interpreted. Given that, it is now known that ARID1A is a bona fide tumor suppressor gene in OCCC, we applied this principle to the evaluation of ARID1A mutations in other tumor types. As described below, we studied more than 700 different neoplasms of seven different types using Sanger sequencing to determine the contribution of ARID1A alterations to tumorigenesis in general.

Somatic mutations were identified in 43 of the 759 neoplasms studied (6%) (Table 1). Eight neoplasms contained two or three (one case) different mutations, presumably on different alleles, so the total number of mutations was 52. A relatively high frequency of mutations was observed in neoplasms of the colon (10%; 12/119), stomach (10%; 10/100), and pancreas (8%; 10/119). Though only a small number of prostate tumors was available for study, we identified two carcinomas with mutations among the 23 studied. Mutations were observed in three of 125 (2%) medulloblastomas, in four of 114 (4%) breast cancers, and in two of 36 (6%) lung carcinomas (Table 1; Fig. 1). No mutations were observed among 34 glioblastomas or 89 leukemias tested.

Table 1. Mutations in the Chromatin Remodeling Gene, ARID1A
SampleTumor typeNucleotide (genomic)bNucleotide (cDNA)cAmino acid (protein)Mutation typeMSI status
  1. a

    aMutation previously reported.

  2. b

    bGenomic co-ordinates refer to hg18.

  3. c

    cReference sequence CCDS285.1.

  4. d

    MSI, microsatellite instability; MSS, microsatellite stable; ND, not determined.

399Breastg.chr1:26928914delCc.1323delCFsIndelMSS
3814Breastg.chr1:26979235G>Ac.6259G>Ap.G2087RMissenseMSS
5887Breastg.chr1:26978695A>Tc.5719A>Tp.I1907FMissenseMSS
C-122Breastg.chr1:26965396C>Tc.2830C>Tp.Q944XNonsenseMSS
Co001Colong.chr1:26896495delGc.1014delGFsIndelMSI-high
Co001Colong.chr1:26973994delCc.4689delCFsIndelMSI-high
Co014Colong.chr1:26970279delAc.3281delAFsIndelMSI-high
Co024Colong.chr1:26970342delCc.3344delCFsIndelMSI-high
Co024Colong.chr1:26978524delGc.5548delGFsIndelMSI-high
Co038Colong.chr1:26973659delCc.4354delCFsIndelMSI-high
Co038Colong.chr1:26978524delGc.5548delGFsIndelMSI-high
Co083Colong.chr1:26978524delGc.5548delGFsIndelMSI-high
Co097Colong.chr1:26978524dupGc.5548dupGFsIndelMSI-high
Hx132Colong.chr1:26931798delCc.1848delCFsIndelND
Hx132Colong.chr1:26965600_26965602delAACc.2944_2946delAACIn-frame delIndelND
Hx164Colong.chr1:26930536C>Tc.1657C>Tp.Q553XNonsenseMSS
Hx245Colong.chr1:26979204C>Ac.6228C>Ap.Y2076XNonsenseMSS
Hx290Colong.chr1:26978814_26978820dupACAGAGC (hom)c.5838_5844dupACAGAGCFsIndelMSS
Hx308Colong.chr1:26978810_26978811insAGCACAGc.5834_5835insAGCACAGFsIndelND
Hx326Colong.chr1:26962098_26962099dupTAc.2467_2468dupTAFsIndelMSS
G07Gastricg.chr1:26896360dupCc.879dupCFsIndelMSI-high
G08Gastricg.chr1:26896308delGc.827delGFsIndelMSI-high
G13Gastricg.chr1:26974048_26974049delCAc.4743_4744delCAFsIndelMSI-high
G13Gastricg.chr1:26978524delGc.5548delGFsIndelMSI-high
G13Gastricg.chr1:26974277C>Tc.4972C>Tp.R1658WMissenseMSI-high
G18Gastricg.chr1:26978335G>Tc.5359G>Tp.E1787XNonsenseMSS
G21Gastricg.chr1:26978524delGc.5548delGFsIndelMSI-high
G24Gastricg.chr1:26973829T>Ac.4524T>Ap.Y1508XNonsenseMSI-high
G61Gastricg.chr1:26978524delGc.5548delGFsIndelND
G61Gastricg.chr1:26979396delCc.6420delCFsIndelND
G84Gastricg.chr1:26961335dupGc.2357dupGFsIndelMSS
G144Gastricg.chr1:26896335delGc.854delGFsIndelMSS
G280Gastricg.chr1:26896450_26896456delGGGCGCCc.969_975delGGGCGCCFsIndelMSS
L11CLungg.chr1:26965400delGc.2834delGFsIndelND
L17CLungg.chr1:26979379_26979384delATTCTGc.6403_6408delATTCTGIn-frame delIndelMSS
MB118PTaMedulloblastomag.chr1:26896496delGc.1015delGFsIndelMSS
MB155PTMedulloblastomag.chr1:26974198_26974199InsCc.4893_4894InsCFsIndelMSS
MB156PTMedulloblastomag.chr1:26974673delGc.5012delGFsIndelMSS
Pa07CaPancreasg.chr1:26972534C>Tc.3826C>Tp.R1276XNonsenseMSS
Pa37XPancreasg.chr1:26978923_26978924delTGc.5947_5948delTGFsIndelMSS
Pa102CaPancreasg.chr1:26965645G>AIVS10+1G>ASplice siteSplice siteMSS
Pa144XPancreasg.chr1:26959958_26959959insTc.1945_1946insTFsIndelMSS
Pa158XPancreasg.chr1:26961274dupCc.2296dupCFsIndelMSS
Pa166XPancreasg.chr1:26978941C>Tc.5965C>Tp.R1989XNonsenseMSS
Pa194XPancreasg.chr1:26978941C>Tc.5965C>Tp.R1989XNonsenseMSS
Pa194XPancreasg.chr1:26979263C>Gc.6287C>Gp.S2096XNonsenseMSS
Pa197XPancreasg.chr1:26930464C>Tc.1585C>Tp.Q529XNonsenseMSS
Pa198XPancreasg.chr1:26978524dupGc.5548dupGFsIndelMSS
Pa216XPancreasg.chr1:26961380delGc.2402delGFsIndelMSS
SW32Prostateg.chr1:26972768delCc.3977delCFsIndelND
SW32Prostateg.chr1:26978524dupGc.5548dupGFsIndelND
Pr04PTProstateg.chr1:26972790_26972792het_delGCAc.3999_4101delGCAIn-frame delIndelMSI-high
thumbnail image

Figure 1. A: Examples of truncating mutations in ARID1A in gastric, colon, breast, and pancreatic cancers. Arrows indicate the position of the mutation. Note that in the breast primary tumor (399), there were contaminating nonneoplastic cells that reduced the relative peak heights of the mutant alleles. B: Distribution and types of mutations identified in ARID1A to date. Exons are indicated in blue with the ARID (AT-rich interactive domain), DNA-binding domain shown in green, the HIC (hypermethylated in cancer) domain in purple, and the LXXLL (leucine rich) motifs in pink. Black arrows indicate the position of insertion or deletion mutations, red arrows indicate nonsense mutations, blue arrows indicate missense variants, and gray arrows indicate splice site alterations. Mutations listed above the figure represent those reported in this study; those below were identified in Jones et al. [2010] and Wiegand et al. [2010] in ovarian cancers; Gui et al. [2011] in bladder cancer; Varela et al. in renal cancer, and Birnbaum et al. in pancreatic cancer.

Download figure to PowerPoint

As expected for inactivating mutations of a tumor suppressor gene, the mutations were distributed throughout the gene and included nonsense variants, out-of-frame and in-frame small insertions and deletions, as well as a small number (three) of missense changes. Mutations were most commonly observed in a seven-base G tract around position g.chr1:26978524 (genomic coordinates refer to hg18) (c.5548), where there were six single base pair deletions and three duplications among gastric, colon, prostate, and pancreas carcinomas. This G tract is the longest mononucleotide repeat in the coding region and the probability of slippage at mononucleotide repeats clearly increases with run length [Eshleman et al., 1996; Markowitz et al., 1995]. Thirty-eight of the 43 samples with somatic mutations were available for microsatellite instability (MSI) testing. Twelve tumors (six colon, five gastric, and one prostate) were shown to be MSI high, and all carried mutations at mononucleotide tracts in the ARID1A gene (Table 1). It is therefore possible that ARID1A, such as TGFβRII or BAX, is associated with MSI and that the homopolymeric repeat frameshifts may result from defects in mismatch repair [Markowitz et al., 1995; Rampino et al., 1997]. Though the interpretation of mutations in mismatch repair-deficient tumors is challenging [Kern, 2002], the fact that approximately 40% of the CRCs with ARID1A mutations did not have MSI leaves little doubt that ARID1A plays a role in this tumor type.

The identification of mutations in ARID1A in several different types of cancer indicates that this gene has a wider role in human tumorigenesis than previously appreciated. These findings are supported by the demonstration of loss of the ARID1A protein, BAF250a, by immunohistochemistry in 14% of gastric and anaplastic thyroid carcinomas [Wiegand et al., 2011] and by the identification of ARID1A point mutations in 3 of 48 pancreatic cancers by Birnbaum et al. [2011]. More recently, ARID1A mutations have also been observed in 13% of bladder carcinomas [Gui et al., 2011]. In addition, ARID1A appears to be frequently mutated in gastrointestinal tumors displaying high levels of MSI. Mutations in other members of the SWI–SNF chromatin remodeling complex have also been reported. For example, truncating mutations in SMARCA4/BRG1 were identified in three pancreatic cancers, in a medulloblastoma, and in several lung cancers [Jones et al., 2008; Medina et al., 2008; Parsons et al., 2011]. More recently, 41% of renal cancers have been shown to have truncating mutations in the SWI–SNF chromatin remodeling complex gene, PBRM1 [Varela et al., 2011]. In addition, a pattern of somatic mutation of genes involved more generally in chromatin remodeling is starting to appear. MLL3 appears to be involved in a small number of colon and pancreatic cancers and medulloblastomas [Jones et al., 2008; Parsons et al., 2011; Wood et al., 2007]; MLL2 is mutated in 14% of medulloblastomas and a large fraction of non-Hodgkin's lymphomas [Morin et al., 2011; Parsons et al., 2011] and JARID1C is genetically altered in a small proportion of kidney cancers [Dalgliesh et al., 2010]. These data collectively link genetic alterations to epigenetic changes and pave the way for a better understanding of both.

Acknowledgements

  1. Top of page
  2. Abstract
  3. Acknowledgements
  4. References
  5. Supporting Information

We thank J. Ptak, N. Silliman, Lakeshia Copeland for expert technical assistance, Sten Cornelissen (NKI-AVL) for germline DNA isolation, and Evan Brower for assistance in producing figures. N.P., B.V., K.W.K., and V.E.V are co-founders of Inostics and Personal Genome Diagnostics and are members of their Scientific Advisory Boards. N.P., B.V., K.W.K., and V.E.V. own Inostics and Personal Genome Diagnostics stock, which is subject to certain restrictions under University policy. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.

References

  1. Top of page
  2. Abstract
  3. Acknowledgements
  4. References
  5. Supporting Information
  • Birnbaum DJ, Birnbaum D, Bertucci F. 2011. Endometriosis-associated ovarian carcinomas. N Engl J Med 364:483484.
  • Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA. 2010. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463:360363.
  • Eshleman JR, Markowitz SD, Donover PS, Lang EZ, Lutterbaugh JD, Li GM, Longley M, Modrich P, Veigl ML, Sedwick WD. 1996. Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability. Oncogene 12:14251432.
  • Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, Jia W, Chen J, Yang S, Zhou F, Zhao X, Wan S, Ye R, Liang C, Liu Z, Huang P, Liu C, Jiang H, Wang Y, Zheng H, Sun L, Liu X, Jiang Z, Feng D, Chen J, Wu S, Zou J, Zhang Z, Yang R, Zhao J, Xu C, Yin W, Guan Z, Ye J, Zhang H, Li J, Kristiansen K, Nickerson ML, Theodorescu D, Li Y, Zhang X, Li S, Wang J, Yang H, Wang J, Cai Z. 2011. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 43:875878.
  • Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. 2007. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer 46:745750.
  • Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, Kinzler KW, Velculescu VE, Papadopoulos N. 2010. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330:228231.
  • Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:18011806.
  • Kern SE. 2002. Quantitative selection constants. Cancer Biol Ther 1:189194.
  • Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Wilson JKV. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. 1995. Science 268:13361338.
  • Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, Sanchez-Cespedes M. 2008. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 29:617622.
  • Meyerson M, Gabriel S, Getz G. 2010. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 11:685696.
  • Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA. 2011. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298303.
  • Nagl NG Jr, Wang X, Patsialou A, Van Scoy M, Moran E. 2007. Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J 26:752763.
  • Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:18071812.
  • Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettegowda C, Gallia GL, Jallo GI, Binder ZA, Nikolsky Y, Hartigan J, Smith DR, Gerhard DS, Fults DW, VandenBerg S, Berger MS, Marie SK, Shinjo SM, Clara C, Phillips PC, Minturn JE, Biegel JA, Judkins AR, Resnick AC, Storm PB, Curran T, He Y, Rasheed BA, Friedman HS, Keir ST, McLendon R, Northcott PA, Taylor MD, Burger PC, Riggins GJ, Karchin R, Parmigiani G, Bigner DD, Yan H, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. 2011. The genetic landscape of the childhood cancer medulloblastoma. Science 331:435439.
  • Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M. 1997. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967969.
  • Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268274.
  • Stratton MR. 2011. Exploring the genomes of cancer cells: progress and promise. Science 331:15531558.
  • Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA. 2011. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469:539542.
  • Wang X, Nagl NG, Wilsker D, Van Scoy M, Pacchione S, Yaciuk P, Dallas PB, Moran E. 2004. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J 383:319325.
  • Weissman B, Knudsen KE. 2009. Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res 69:82238230.
  • Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG. 2011. Loss of BAF250a (ARID1A) is frequent in high grade endometrial carcinomas. J Pathol 224:328333.
  • Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. 2010. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:15321543.
  • Wilson BG, Roberts CW. 2011. SWI/SNF nucleosome remodelers and cancer. Nat Rev Cancer 11:481492.
  • Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:11081113.
  • Wu JI, Lessard J, Crabtree GR. 2009. Understanding the words of chromatin regulation. Cell 136:200206.
  • Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. 2009. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765773.

Supporting Information

  1. Top of page
  2. Abstract
  3. Acknowledgements
  4. References
  5. Supporting Information

Additional Supporting information may be found in the online version of this article

FilenameFormatSizeDescription
humu_21633_sm_Mat.pdf163KSupporting Material

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.